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Prion diseases are fatal neurodegenerative disorders of the central nervous system characterized by the
accumulation of a protease resistant form (PrPSc) of the cellular prion protein (PrPC) in the brain. Two
types of cellular prion (PrPC) compounds have been identified that appear to affect prion conversion
are known as Effective Binders (EBs) and Accelerators (ACCs). Effective binders shift the balance in favour
of PrPC, whereas Accelerators favour the formation of PrPSc. Molecular docking indicates EBs and ACCs
both bind to pocket-D of the SHaPrPC molecule. However, EBs and ACCs may have opposing effects on
the stability of the salt bridge between Arg156 and Glu196/Glu200. Computational docking data indicate
that the hydrophobic benzamide group of the EB, GFP23 and the 1-(3,3-dimethylcyclohexylidene)piperi-
dinium group of the ACC, GFP22 play an important role in inhibition and conversion from SHaPrPC to
SHaPrPSc, respectively. Experimentally, NMR confirmed the amide chemical shift perturbations observed
upon the binding of GFP23 to pocket-D of SHaPrPC. Consistent with its role as an ACC, titration of GFP22
resulted in widespread chemical shift changes and signal intensity loss due to protein unfolding. Virtual
screening of a ligand database using the molecular scaffold developed from the set of EBs identified six of
our compounds (previously studied using fluorescence quenching) as being among the top 100 best bin-
ders. Among them, compounds 5 and 6 were found to be particularly potent in decreasing the accumu-
lation SHaPrPSc in ScN2a cells with an IC50 of 35 mM and 20 mM.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Prion diseases or transmissible spongiform encephalopathy’s
(TSEs) that include Creutzfeldt-Jakob disease (CJD), chronic wast-
ing disease (CWD), scrapie, and bovine spongiform encephalopathy
(BSE) are neurodegenerative diseases characterized by the accu-
mulation of a protease resistant form of the prion protein (PrPSc)
in the brain.1,2 Currently, no effective therapy or vaccine exists
on these invariably fatal TSEs. Studies have shown that disease
associated forms of prion arises when the a-helical rich normal
cellular prion protein (PrPC) gets converted to a b- sheet rich dis-
ease-related isoform PrPSc.3 The propensity of PrP misfolding isdetermined by the difference in electrostatic energies namely salt
bridge and solvation energies between folded and misfolded states
and the magnitude of energy barrier separating them.4 The disrup-
tion of these electrostatic salt bridges in native PrPC leads to the
formation of more hydrophobic PrPSc. Structurally, these salt
bridges are differentiated into local and non-local based on the
participating residues and their proximity in sequence. Local salt
bridges, like Asp148-Glu152 in a1, Asp208-Glu211 in a3, and Arg164-
Asp167 between b2 and the following loop, serve to stabilize sec-
ondary structural elements of the protein; nonlocal salt bridges,
like Arg156-Glu196, Arg164-Asp178, and Glu146-Lys204, help to hold
these elements together in the overall tertiary fold4 . There is
increasing interest in developing an antiprion compound to inhibit
the conversion of PrPC to PrPSc to provide control over TSE disease
keeping the salt bridges intact. While the mechanisms of prion
propagation are not well understood, numerous studies have
Fig. 1. Binding mode of the inhibitor (GFP23) in the binding pocket-D of SHaPrPC.
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sion of PrPC to PrPSc thus preventing neurodegeneration.5 Experi-
mental studies of various compounds (polyanionic agents, Congo
red, amphotericin B, porphyrins, and phenothiazine derivatives,
such as quinacrine) have had antiprion effects, reducing PrPSc accu-
mulation in cell culture models of prion diseases.6 In comparison to
the known compounds, an antiprion compound known as GN8 was
shown to be more effective than quinacrine in preventing the accu-
mulation of PrPSc.7 Nuclear Magnetic Resonance (NMR) studies on
the chemical shift changes caused by GN8 binding show that the
major binding region is located in the C-terminal domain of PrPC.8
Furthermore, 2-aminothiazoles that improved metabolic stability
and membrane permeability in mice represents a promising new
class of drug leads for treating prion diseases. Some of these com-
pounds potently inhibit the conversion of PrPC to PrPSc.9 Later, a
variety of structurally diverse compounds were identified as
potent inhibitors or accelerators of PrPC. These compounds were
classified into effective binders (EBs), effective low affinity binders
(ELBs), non-effective binders (NEBs), non-effective low affinity bin-
ders (NELBs), or accelerators (ACCs).10 Recently, the analog of
indole, IND22308 produced a large effect in HTS and SPC assays
with 70% and 94% inhibition. In addition, the compound showed
no effect on cell viability in both stationary phase and in dividing
cells elucidating the antiprion activity with an EC50 of 7.5 and
1.6 mM.11 Although various strategies for drug discovery of anti-
prion compounds have been reported, there have been no reports
on the binding regions of antiprion compounds that include evi-
dence for interaction with specific amino acid residues. To design
more potent and highly specific antiprion compounds for TSE dis-
ease, molecular recognition of compounds by the prion protein has
to be clearly understood. In this study, to elucidate the mechanism
of PrPC stabilization or conversion to PrPSc, and to understand the
individual atomic contributions that play an important role in
the antiprion activity, the binding of a series of the known com-
pounds, EBs and ACCs to SHaPrPC were examined using molecular
docking. The nomenclature of the compounds was exactly repre-
sented the same in the published paper for better understanding.10
In addition, NMR studies were conducted for two representative
known compounds, GFP23 (EB, C19H30N5) and GFP22 (ACC,
C21H24N2O2) to examine their effect in stabilizing or misfolding
of SHaPrPC. Further, 3D QSAR models were built for these known
compounds EBs and ACCs using HQSAR (Hologram quantitative
structure activity relationship, Tripos Inc) and CoMFA (compara-
tive molecular field analysis) to understand the individual atomic
contributions that play an important role in the biological activity
and intermolecular interactions against SHaPrPC.12 To facilitate
further development of new antiprion compounds, a molecular
scaffold was generated by the set of known compounds EBs. Virtual
screening of the compound database using newly generated scaf-
fold identified a total of 100 compounds with 85% similarity. Out
of these 100 compounds, six compounds (Bionet1G037 ((5-(3,4-
dimethoxyphenyl)-4-methylpyrimidin-2-amine) (C13H15N3O2)),
Bionet5T0214 ((4,5-bis(4-methoxyphenyl)pyrimidin-2-amine
(C18H17N3O2)), Bionet6T0265 ((4,5-bis(4-methoxyphenyl)-1,3-thi-
azol-2-amine (C17H16N2O2S)), chembridge6413213 ((N-[4-(2,5-
Dimethoxyphenyl)-5-methyl-1,3-thiazol-2-yl]-3,4,5-trimethoxy-
benzamide) (C22H24N2O6S)), Chembridge6623338 ((3-{5-[(2,5-
dimethoxyphenyl)amino]-1,3,4-thiadiazol-2-yl}-8-methoxy-2H-
chromen-2-one) (C20H17N3O5S)), and chembridge6872366 ((4-(2,4-
dimethoxyphenyl)-5-methyl-1,3-thiazol-2-amine) (C12H14N2O2S))
had been used previously for fluorescence quenching studies
against SHaPrPC.13 These six representative compounds were fur-
ther investigated experimentally in prion infected ScN2a cells.
They show antiprion activity in reducing the accumulation of PrPSc
in a high-throughput assay using scrapie-infected neuroblastoma
ScN2a cell lines at a minimum concentration of 20 mM. All of thesesix representative antiprion compounds were non-toxic to ScN2a
cell culture. Taken together, the results suggest that the antiprion
activity of these six compounds is mainly mediated by binding to
pocket-D of SHaPrPC. Further, the intact salt bridge between
Arg156/Glu196/Glu200 may play an additional role in the prevention
of formation of SHaPrPSc.2. Results and discussion
2.1. Effective binders (inhibitors) stabilize pocket-D through hydrogen
bonding network
To examine the mode of binding of EBs, we performed blind
docking with a set of compounds known as EBs against SHaPrPC
using the dock module of MOE software suite 2014.10 Docking
studies indicated that these ligands to bind in a hydrophobic
pocket-D where the known compounds 2-aminothiazoles bound.
The benzamide group of EB (GFP23, C19H30N5) orients towards
the binding pocket while the 1H indole group is solvent exposed
with the interaction energy of 12.6 kcal/mol (Fig. 1).
In the docked complex, EB (GFP23, C19H30N5) made two hydro-
gen bonds with Asn197 (N) and Asp202 (Od1) and makes
hydrophobic contacts with Arg156 (N), Asn197 (N), Phe198 (Cb) and
Met206 (C) along with one water molecule in the vicinity of the
binding pocket. The benzamide oxygen interacts with the nitrogen
atom of Asn197 and also makes a hydrogen bond to Thr192 through
water. In addition, the oxygen atom attached to 1H-indole group
interacts with the positively charged residue Arg156 at 3.01 Å dis-
tance. The carbon atoms C5 and C9 of the benzamide made
hydrophobic contacts with the residues Met206 and Phe198 at
3.55 and 3.23 Å distances, respectively. This predicted orientation
of binding indicates that the presence of the benzamide group
attached to 1H-indole plays an important role in inhibition
SHaPrPC conversion. The experimental dissociation constant (Kd)
was determined to be 51.2 ± 12.2 mM.10 The compound2 (GFP06,
C20H22N2O) also has a good docking score with the interaction
energy of 11.1 kcal/mol. Due to its bigger size, the tetrahydron-
aphthalen-2-yl acetamide group occupies more space in the bind-
ing site making a hydrogen bond with oxygen atom of Asn197 and
two hydrophobic contacts with Phe198 (C2) and Met206 (C). The 1H-
indole nitrogen on the pocket surface makes a water mediated
interaction with Gly195 while the acetamide group accepts elec-
trons from Tyr149 (Fig. S1A). The estimated Kd value was deter-
mined to be 48.6 ± 20.3 mM.10 The tricyclic group of the
compound3 (GPF04, C18H23N3O2S) made a hydrogen bond with
Fig. 2. Pharmacophores of the inhibitor (GFP23) in the binding pocket of SHaPrPC.
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pocket. The nitrogen atom of 2,3-pyrimidin-4 methyl accepts elec-
trons from Tyr149 while methyl cyclohexamine enters deeper into
the pocket interacting with Phe198 (Cb), Ile203 (C1) with the total
interaction energy of 11.3 kcal/mol (Fig. S1B). The compounds 4
and 7 (GFP75, C17H15N3O2S) and (GJP45, C18H19N3OS) have the
same affinity of 12.2 kcal/mol, without showing any hydrogen
bonds with SHaPrPC. The indole group of compound4 makes two
hydrophobic contacts with Phe198 and Met206, but 2-(thieno[2,3-
d]pyrimidin-4-methyl is exposed and makes a HAPi interaction
with Glu196 (Fig. S1C and F). The nitrogen atom of 2,3-pyrimidin
of compound4 makes a water-mediated interaction with the posi-
tively charged residue Arg156. The 3-amino-N-cyclopentylthieno
group of the compound7 (GJP45, C18H19N3OS) penetrates deeply
into the binding pocket and makes five hydrophobic contacts with
Met154, Phe198, Ile205, Met206 and Val209 (Fig. S1F). The amino-N-
cyclopentylthieno also has a water-mediated and HAPi interac-
tions with Arg156, Glu196 and Asp202. The compounds 5 & 10
(GFP80, C21H21N3O2 & GJP52, C23H20N20) also have equal affinity
with the interaction energy of 12.1 kcal/mol. The di-hydroquina-
zolin ring of compound5 occupies the surface of the pocket and
forms hydrogen bonds with Arg156 and Asn153 while the naph-
thalene ring occupies a hydrophobic patch, contacting Phe198
(Cb), of Ile184 (C2), Ile203 (C1) and Met206 (Cb) (Fig. S1D). This com-
pound also makes water-mediated hydrogen bonds with Glu196,
Arg156 and Gly195 in the vicinity of the binding site. However, N-
(pyridin-2-ylmethyl)acetamide group of compound10 orients
towards the hydrophobic patch making a hydrogen bond with
Asn197 and hydrophobic contacts with Phe198 (Cb), Ile203 (C1) and
Met206 (C). The tricyclic group makes HAPi interaction with
Arg156 on the surface of the binding pocket (Fig. S1I). The tricyclic
group (6-methyl-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-one) of
compound6 (GJP14, C21H28N2O2) is placed above the surface of
the binding pocket showing HAPi interaction with Arg156. The
piperidine group is oriented towards the hydrophobic patch of
the pocket and forms hydrogen bonds and hydrophobic contacts
with Asn197, Asp202, Phe198 and Met206. The residue Arg156 donates
electrons to the hydroxyl group of the compound along with
Asn197, while Tyr149 donates its electrons to the oxygen attached
to the tricyclic group (Fig. S1E). The piperidine group also has an
ionic interaction with negatively charged Asp202 with the total
interaction energy of 12.0 kcal/mol. This binding orientation
showed that the piperidine group of compound6 is mainly respon-
sible for the inhibition of prion pathogenic conversion from PrPC–
PrPSc. Previous experimental studies conducted on a total of 47
derivatives of compound6 revealed that, a tricyclic aromatic scaf-
fold, a hydroxy group, and a terminal amino group were deter-
mined to be the basic requirements for antiprion activity.14 NMR
analysis also showed that this compound6 binds to same region
of PrPC that corresponds to that of GN8 which undergoes a global
fluctuation in a time scale of micro- to milliseconds.15 The com-
pound8 (GJP49, C19H24N2O2S) had a higher binding affinity com-
pared to other compounds, with the total binding energy of
14.1 kcal/mol (Fig. S1G). The methyl group on the C1 carbon
atom of 2-piperidine makes three hydrophobic contacts with
Phe198, Met206 and Ile203, while the dioxino[2,3-g]quinolone group
interacts with an OH group of Tyr140 via a hydrogen bond. Since
this compound does not have any water mediated-interactions in
the vicinity of the binding site, the bulky group of 2,3-dihydro[1,4]-
dioxino[2,3-g]quinolone attached to 7-{[2-(piperidin-1-yl)ethyl]-
sulfanyl} is responsible for higher binding energy compared to
other tricyclic groups of compounds 3 & 6. Finally, the compound
9 (GJP51, C18H20N2OS) had lower binding energy compared to all
the other EBs with the binding energy of 10.6 kcal/mol. The thio-
phen group is oriented towards the hydrophobic portion of the
binding pocket making a HAPi interaction with Tyr157 (Fig. S1H).The (2Z)-2-(2,3,3-trimethyl-3,4-dihydroisoquinolin-1(2H)-yli-
dene)ethanamide is placed on the surface without any contacts
with SHaPrPC. These docking studies and previous experimental
data confirms that all these EB’s were commonly bind to major
binding pocket-D of SHaPrPC and may keep the salt bridge between
Arg156 and Glu196 intact 10. Overall, ligand protein interactions
show that Asn197, Phe198, Thr201, Asp202, Ile203, Ile205 and Val206
residues acts as common pharmacophores of all these EB’s pre-
venting the prion conversion to pathogenic form from SHaPrPC to
SHaPrPSc (Fig. 2).2.2. Accelerators (ACCs) attenuates PrP flexibility
To predict the role of the residues in protein misfolding, second
set of the molecules known as accelerators (ACCs) were docked
with SHaPrPC.10 The 1-{3-[2-(4,6-dimethylpyrimidin-2-yl)hy-
drazin-1-yl] group of compound1 (GFP22, C21H24N2O2) orients
towards Tyr149 on the surface of the pocket making a hydrogen
bonded with the hydroxyl group of Tyr149. The nitrogen atom of
hydrazine donates a proton to the hydroxyl group of Tyr149 (Fig. 3).
The 5,5-dimethylcyclohex-3-en-1-ylidene}-15-piperidin-1-
ylium ring orients towards Glu196 without making any contacts
with pocket-D of SHaPrPC. This compound1 binds with a high
interaction energy of 13.7 kcal/mol. The compounds 2, 3 and 4
bind with equal affinities, 11.1, 11.2 and 11.5 kcal/mol,
respectively. The tricyclic group of the compound2 (GFP88,
C18H20N4S) N-(propan-2-yl)-2-(pyridin-3-yl)-4b,5,6,7,8,8a-hex-
ahydro[1]benzothieno[2,3-d] oriented into the binding pocket
while pyrimidin-4-amine was above the surface of the pocket mak-
ing a HAPi interaction with Arg156. The nitrogen atom of pyrim-
idin-4-amine also makes water-mediated interactions with
Arg148 and Asn153 (Fig. S2A). However, the nitrogen atom of the tri-
cyclic group interacts with the negatively charged Glu196 while the
cyclohexane ring of the tricyclic group shows contacts with Phe198.
The cyclohexane ring of compound3 (GFP92, C20H27N3O3) occupies
a deeper part of the binding pocket-D compared to tricyclic group
while imidazolidine-2,4-dione resides very close to Tyr149 and
Arg156 and makes two hydrogen bonds with Met206 (C) and
Tyr149 (OH) and three hydrophobic contacts with Phe198 (Cb),
Asn153 (O1) and Asp202 (O1). One of the oxygen atoms of imidazo-
lidine-2,4-dione shows hydrogen bond with Tyr149 while the other
Fig. 3. Binding mode of the accelerator (GFP22) in the binding pocket-D of SHaPrPC.
Fig. 4. Pharmacophores of the accelerator (GFP22) in the binding pocket of SHaPrPC.
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Gly195 (Fig. S2B). The N-(2-phenylethyl)propanamide is placed
above the surface of the pocket and shows no contacts with
pocket-D. The data obtained for compound4 (GFP94, C18H19CIN2-
O2) indicate that the nitrogen atom of the N-(4-chloro-2-meth-
oxy-5-methylphenyl) interacts with Asn153 through a hydrogen
bond while chlorine has hydrophobic contacts with the backbone
atoms of Phe198 and the side chain of Met206. The 2,3-dihydro-
1H-indol-1-yl group is on the surface and has no contacts with
pocket-D while the acetamide group has water-mediated interac-
tions with Gly195 and Glu196 (Fig. S2C). The total interaction energy
with the protein is 10.2 kcal/mol. The molecular docking per-
formed for compound5 (GFP39, C22H25N3O3) suggests that the ter-
minal methybenzene and cyclohexyl rings occupy space on the
surface of the protein because of a larger chain length between
the two rings. The nitrogen atom of N-(cyclohexylmethyl)ac-
etamide penetrates slightly deeper into the pocket making con-
tacts with Tyr149 and Asp202 through hydrogen bonds while
pyrolidine has a hydrophobic contact with Phe198. The nitrogen
atom also makes a water-mediated interaction with Arg156
(Fig. S2D). The final model obtained for compound6 (GJP41, C18-
H28N4OS) showed that 4-propyl-1,2,4-triazolidin-3-yl}pyridine
penetrates very deeply into the pocket while cyclohexane car-
baldehyde is exposed to the surface. Compound6 makes three
hydrogen bonding and hydrophobic interactions with Tyr149,
Asp202, Asn153 and Phe198 and has a higher interaction energy,
12.4 kcal/mol compared to compounds 2, 3, 4 and 5, respectively
(Fig. S2E). One of the nitrogen atoms of 1,2,4-triazolidin of com-
pound6 accepts electrons from Arg156 while the other nitrogen
donates electrons to oxygen atom of Asp202. The nitrogen atom also
donates protons to backbone of Asn153 that occupies between
pro158 and Tyr157. These results also show that all these ACCs bind
to pocket-D and may disturb the salt bridge between Arg156/
Glu196/Glu200 which might play an important role in prion conver-
sion from SHaPrPC to SHaPrPSc. Overall, ligand protein interactions
show that Asn153, Arg156, Glu196, Phe198 and Asp202 residues act as
common pharmacophores of these compounds accelerating the
prion conversion to pathogenic form from SHaPrPC to SHaPrPSc
(Fig. 4).
2.3. NMR studies of EB (GFP23) and ACC (GFP22)
The binding site for the EB (GFP23) and ACC (GFP22) was inves-
tigated using heteronuclear NMR spectroscopy on a 15N-labeled
sample of the SHaPrPC (amino acids 90–232 with C-terminal
6 -His tag). Titration of GFP22 resulted in widespread chemical
shift changes and signal intensity loss due to protein aggregation(Fig. 5A). Fig. 5B showed the signal attenuation and chemical shift
changes in the 15N-HSQC spectrum of the SHaPrPC after addition of
EB (GFP23) (5:1, ligand/protein molar ratio). The first set of atten-
uated signals (Y157, G195, and T199) were located in pocket-D
located between the helices a2, a3 and loop 4, which is considered
a hotspot for inhibition of conversion of SHaPrPC to SHaPrPSc with
antiprion compounds.16 The second set of attenuated signals were
seen in an unstructured loop with the residues G123, M129, V166, and
Y169 adjacent to a1, which also contains two tyrosine’s and a tryp-
tophan residue (Fig. 5B).
In addition, a first region of the protein (pocket-D) undergoes
conformation change, due to small changes in lengths of the hydro-
gen bond or other minor conformational/dynamic changes. How-
ever, no NOEs were observed between the inhibitor and the
region in pocket-A, which consists of the ‘amylome’ residues
169NNQNNY175.14 Long-range effects of this region and the distal
residues in a3 have been noted in previous studies.17 Whether
these distal effects on the amylome region upon inhibitor binding
have any significance or are an inconsequential artifact has yet to
be determined.2.4. HQSAR study of EBs and ACCs
Since there are a variety of differing structures in both the EB
(GFP23) and ACC (GFP22) we wished to examine which areas of
each molecule were important for binding to PrPC and inhibiting
PrPsc formation. In an effort to create a scaffold on which to build
new inhibitors of prion formation, we first performed a quantita-
tive structure activity relationship using HQSAR in order to asses
which portions of EBs and ACCs were important for their respective
activity. The ability of each EB to inhibit the formation of PrPSc was
obtained from previously published western blots results that
examined the ability of compounds to block PrPSc formation. The
EBs were then fragmented in silico and the composite data set used
to examine which fragments correlated with biological activity. To
obtain the best cross validated r2 of the model, HQSAR analysis was
performed with a set of factors such as fragment size, number of
fragments, atom types (A), bond types (B), atom hybridization or
connectivity (C), hydrogen bond and donor (H). The rules to deter-
mine the type of unique structural features of the model comps
were provided by user-selectable flags including A, B, C and H.
Atom flag differentiates the fragments based on different types of
element. Different bond types of these fragments were distin-
guished using bond’s flag. The hybridization state of the atoms in
the fragment was distinguished using connection flag. Hydrogen
Fig. 5. 15N-HSQC titration spectra of an inhibitor (GFP23) (Fig. A) and accelerator (GFP22) (Fig. B) of SHaPrPC90–232 destabilization. General random coil shifts readily present
at a 1:5 ratio of protein to ligand. The bound box was defined by the residues presenting the largest chemical shift changes observed upon ligand titration for the inhibitor,
GFP23 (Fig. C) and the accelerator, GFP22 (Fig. D).
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the fragment. In the initial HQSAR analysis, several combinations
of these parameters were considered including the default frag-
ment size of 4–7 atoms including atom types (A), bond types, (B),
connectivity (C), and hydrogen (H). HQSAR analysis was performed
over the 12-default series of hologram lengths of 53, 59, 61, 71, 83,
97, 151, 199, 257, 307, 353, and 401 bins. Next, the partial least
squares (PLS) analysis that gave the least cross-validated standard
error (SEcv) was selected for obtaining the best hologram length
(L) and optimum number of components (N). Finally, an HQSAR
model (hologram) was derived from the training set. The results
obtained from HQSAR analyses for the 21 training set comps using
several fragment distinction combinations are summarized in
Table 1.
The best HQSAR model was generated (descriptors: atoms,
bonds, hydrogen’s, donors and acceptors; fragment length: 4.7,
hologram length: 353). The PLS analysis for the training set yielded
the best model (Table 3) with a cross-validated q2 value of 0.230
with five optimal components, and non-cross validated r2 valueof 0.97 with a standard error of 0.077. The PLS analysis was
repeated using the best fragment distinction obtained from previ-
ous step to check its influence on key statistical parameters. The
statistical results of the different fragment sizes evaluated (2–5,
3–6, 5–8, 6–9, 7–10 and 8–11) are summarized in Table 2.
The results show that the best statistical result was obtained
with the fragment size 4–7. The predictive ability of the best
HQSAR model derived using the 21 training set molecules was val-
idated by external test set of 4 compounds randomly picked
(marked asterisk in Table 1), giving satisfactory predictive r2 value
of 0.73 (Table 3).
The experimental and predictive activities of both training set
and test set were shown in Table 4. Based on the HQSAR model,
the relationship between the experimental and predicted activities
of both the training and test set were fairly predicted with r2 value
of 0.73 and residual values less than one log unit (Fig. S3 and
Table 4). In addition to predicting the activities of unknown
molecules, the QSAR model also provides clues to the relation of
different molecular fragments of biological activity.
Table 1
HQSAR analysis for various fragment distinctions of BE and BNE using fragment size (4–7).
Model No Fragment Distinction Statistical parameters
q2 r2 SEE N HL
1 A/B
2 A/B/C – – – – –
3 A/B/C/H – –
4 A/B/C/Ch 0.050 0.869 0.081 3 307
5 A/B/C/H/Ch 0.230 0.970 0.077 5 353
6 A/C/DA –
7 A/B/C/H/DA 0.104 0.983 0.084 5 353
8 A/B/H 0.235 0.983 0.077 5 199
9 A/B/H/DA 0.127 0.781 0.077 3 353
10 A/B/C/DA
11 A/B/Ch/DA
12 A/B/H/Ch 0.072 0.566 0.078 2 151
13 A/B/DA
14 A/B/Ch
15 A/C/Ch/DA
16 A/C/H/DA 0.511 0.994 0.064 6 97
q2 Cross-validated correlation coefficient, r2 non-cross-validated correlation coefficient, SEE standard error of estimate, N number of statistical components, HL hologram
length, A atoms, B bonds, C connection, H hydrogen atoms, Ch chirality, DA donor and acceptor
aThe model chosen for HQSAR analysis.
Table 2
Influence of various fragment sizes using the best fragment distinction combination (A/C/Ch/DA) using HQSAR analysis.
Model No Fragment Size Statistical parameters
q2 r2 SEE N HL
1 2–5 –
2 3–6
4 5–8 0.067 0.809 0.080 3 97
5 6–9 – – – –
6 7–10 – – – – –
7 8–11 – – –
Table 3
Summary of HQSAR analysis for the set of BE and accelerators used in the study.
PLS analysis HQSAR
Components 1
q2 0.733
Conventional r2 0.99
Standard error of estimate 0.046
F values 63.243
Bootstrapping
r2 0.737
Standard error of estimate boot strapping 0.042
Progress scrambling
Q2 0.637
cSDEP 0.05
dq20 /dr20yy 1.7
Predictive r2 0.718
Table 4
Predicted EC50 values for binder’s effective (BE) and accelerators using HQSAR
analysis.
Compound Experimental EC50 (mM) Predicted EC50 (mM) residual
gfp66* 7.02 7.189 0.156
gpf04 7.16 7.15 0.024
GFP33 7.17 7.18 0.003
GFP72 7.17 7.169 0.014
gfp75 7.17 7.164 0.019
GFP16 7.17 7.169 0.014
GJP58 7.18 7.18 0.013
gfp80* 7.18 7.277 -0.088
GJP43 7.19 7.193 0.009
GFP22 7.19 7.204 -0.002
GJP30 7.2 7.198 0.014
gfp88 7.23 7.232 0.011
GJP91 7.23 7.24 0.001
GJP50 7.24 7.244 0.007
GFP01* 7.24 7.313 -0.065
gjp51 7.24 7.231 0.020
gfp06 7.25 7.252 -0.008
GJP52 7.26 7.264 0.006
GJP32 7.27 7.261 0.010
GJP14 7.28 7.279 0.010
gjp36 7.29 7.289 0.01
GJP49 7.32 7.321 0.007
gjp45* 7.37 7.28 0.099
GFP07 7.42 7.418 -0.006
GFP23 7.43 7.43 0.004
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accelerator (GFP22) using HQSAR
The HQSAR model is graphically represented in the form of con-
tribution maps where the color of each atom reflects the contribu-
tion of that atom to the molecule’s overall activity. The atoms with
different color codes reflects the degree of contribution to the over-
all antiprion activity of the compound. The atoms with poor (or
negative) contributions to the biological activity was shown with
red end of the spectrum (red, red orange, and orange), while the
atoms with favorable (positive) contributions was shown with
green end (yellow, green blue, and blue). Atoms with intermediate
contribution was shown in white color. Fig. 6A and B shows theindividual atomic contribution to the EB (GFP23) and ACC
(GFP22) to its antiprion activity.
The results indicate that the benzamide and 1H-indole groups
mainly contributes the overall antiprion activity of the EB
Table 5
Dataset used for HQSAR study.
Comp IUPAC name Mean level of PrPSc ± SD (%)
GFP66* 2-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-ylsulfanyl)-N-(tetrahydrofuran-2-ylmethyl) acetamide 93.68 ± 13.69
GFP04 2-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yloxy)-N-(2-methylcyclohexyl)acetamide 68.77 ± 11.7
GFP33 N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide 66.94 ± 0.11
GFP72 (4R)-1-[2-Oxo-2-(piperidin-1-yl)ethyl]-30 ,40-dihydro-2H,20H,5H-spiro[imidazolidine-4,10-naphthalene]-2,5-dione 67.11 ± 33.65
GFP75 1-(2-Methyl-2,3-dihydro-1H-indol-1-yl)-2-(thieno[2,3-d]pyrimidin-4-yloxy)ethanone 67.43 ± 23.22
GFP16 1-(3,4-Dihydroquinolin-1(2H)-yl)-2-[(2R)-2-propyl-2,3-dihydro-1H-benzimidazol-1-yl]ethanone 67.24 ± 1.24
GJP58 N-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-(2-oxobenzo[cd]indol-1(2H)-yl)acetamide 65.03 ± 4.59
GFP80* 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)propanamide 65.01 ± 35.45
GJP43 N2-Cyclopentyl-N1-phenylpyrrolidine-1,2-dicarboxamide 63.16 ± 7.91
GJP22 1-(2,3-Dihydro-1H-indol-1-yl)-2-[(3R)-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-3-yl] ethanone 63.70 ± 5.23
GJP30 2-(Cyclopentylamino)-2-oxoethyl 2,3-dihydro-1H-cyclopenta[b]quinoline-9-carboxylate 62.89 ± 3.93
GJP91 N-[(2R,3S,3aR,7aS)-3-Cyanooctahydro-1-benzothiophen-2-yl]-2-[(2R)-2-methylpiperidin-1-yl]acetamide 58.78 ± 5.89
GJP50 4-[2-(3,4-Dihydroquinolin-1(2H)-yl)-2-oxoethyl]-2H-1,4-benzoxazin-3(4H)-one 57.55 ± 4.88
GFP01* N-(Ethenylcarbamoyl)-2-acetamide 56.73 ± 13.15
GJP51 (2E)-N-(Thiophen-2-yl)-2-(2,3,3-trimethyl-3,4-dihydroisoquinolin-1(2H)-ylidene)ethanamide 57.44 ± 1.62
GFP06 2-(2,3-Dihydro-1H-indol-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl) acetamide 55.33 ± 12.35
GJP52 54.71 ± 9.21
GJP32 (1R)-1,4-Dihydronaphthalen-1-yloxo[(2R)-1,2,3,4-tetrahydronaphthalen-2-ylamino]acetate 53.05 ± 10.72
GJP14 51.32 ± 7.76
GJP36 2-[4-(Cyclobutylcarbonyl)-1,4-diazepan-1-yl]-8-methylquinoline-3-carbonitrile 50.62 ± 21.26
GJP49 8-Methyl-7-{[2-(piperidin-1-yl)ethyl]sulfanyl}-2,3-dihydro[1,4]dioxino[2,3-g]quinoline 47.40 ± 19.89
GJP45* 3-Amino-N-cyclopentyl-8-methylthieno[2,3-b]quinoline-2-carboxamide 41.85 ± 18.82
GFP07 2-[2-(Butylamino)-1H-benzimidazol-1-yl]-1-(2,3-dihydro-1H-indol-1-yl) ethanone 37.33 ± 4.23
GFP23 N-[1-(2,3-Dihydro-1H-indol-1-yl)-3-methyl-1-oxopentan-2-yl]benzamide 36.78 ± 0.63
Fig. 6. HQSAR contribution maps of inhibitor (GFP23) (Fig. A) and accelerator (GFP22) (Fig. B) for prion protein SHaPrPC inhibition and acceleration.
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cate positive contribution to the activity of the EB, suggesting that
this is a pharmacologically important group for effective binders
that inhibit SHaPrPSc formation by stabilizing SHaPrPC. The partic-
ular atoms of the EB with positive contributions to activity include,
C1, C4, H4, C7, H7, C8, H8, C12, H12, H1, C20 and H21. The attach-
ment of 5,5-dimethylcyclohex-3-en-1-ylidene}-1?5-piperidin-1-
ylium to the backbone of 1-{3-[2-(4,6-dimethylpyrimidin-2-yl)
hydrazin-1-yl] creates a negative contribution to the antiprion
activity of ACC shownwith red color (Fig. 6B). To verify predictabil-
ity of the constructed HQSAR model based on the training set, four
compounds were selected as testing set for validation. The
predicted bioactivities of the training and test sets were shown
in Table 5. The correlation between the predicted and experimental
results was depicted in Fig. S3. The PLS analysis on the test set
released cross validated q2 value of 0.73 and r2 value of 0.73 with
a standard error of 0.046 (Table 4). In addition, the predictive r2
value of 0.73 may suggest a satisfactory model. All of the statistical
results demonstrate that the HQSAR model is fairly reliable with
good predictive ability and could be helpful in discovering new
antiprion compounds. Superimposition of the EB and ACC com-
pounds showed that biologically active groups of 1-oxopentan-
2-yl]benzamide of EB and 1-{3-[2-(4,6-dimethylpyrimidin-2-yl)hydrazin-1-yl] of ACC align each other with an overall alignment
score of -59 kcal/mol (Fig. 7).2.6. Docking versus CoMFA of the EB (GFP23) and ACC (GFP22)
The CoMFA analysis of steric and electrostatic contour maps of
the EB and ACC is shown in Fig. 8. These contour maps were com-
pared and contrasted with the docking orientations in the binding
site of SHaPrPC. The green contours near the benzamide group of
the EB (GFP23) fell in the hydrophobic pocket-D formed between
a2 and a3, while the green counters near pyramidine-2 amine
group of ACCs (GFP22) is solvent exposed. The aliphatic side chains
of Phe198, Ile184, Ile205, Val209, and Val210 lining the hydrophobic
pocket make contacts with benzamide group of the EB (GFP23)
(Fig. 8A). This indicates that benzamide group of the EB (GFP23)
is favorable for SHaPrPC inhibition and thus preventing the conver-
sion from SHaPrPC-SHaPrPSc while 1-(3,3-dimethylcyclohexyli-
dene)piperidinium of the ACC (GFP22) is favorable for prion
misfolding accelerating the conversion of PrPC to PrPSc (Fig. 8B).
Thus, contour maps generated by CoMFA are in good agreement
with our docking studies which indicates that the results are highly
reliable.
Fig. 7. Superimposition of Inhibitor (GFP23) and accelerator (GFP22) using MOE
software suite. Inhibitor is represented in magenta while the accelerator is
represented in orange color.
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A total of 1000 compounds were generated by recap synthesis
with a set of 10 identified EB’s GFP04, GFP06, GFP23, GFP75,
GFP80, GJP14, GJP45, GJP49, GJP51 and GJP52. These new
compounds were again docked with SHaPrPC using the same
method described above. The top-ranking molecule 4-[(7-amino-
2,3-dihydro-1,3-benzothiazol-2-yl)oxy]-6,7-dimethoxy-2H-chromen-
2-one had reasonable interactions and geometry fitting in the
pocket-D of SHaPrPC (Fig. 9A). The O24 atom of the molecule
showed hydrogen bonding interactions with O1 of Thr191. Addi-
tionally, two hydrophobic interactions were observed between
the carbon atoms, C10 and C11 of 6,7-diethyl-4-hydroxy-2H-chro-
men-2-one with Cb of Phe198 and C of Met206. The binding mode of
this molecule shows that chromen-2-one group of the ligand
orients deeper into the binding pocket and 2,3-dihydroxy-1,3-
benzothiazol-7-amine group is on the surface region of theFig. 9. Ligand protein interactions of molecular scaffold with pocket-D (Fig.
Fig. 8. CoMFA contribution maps of the inhibitor (GFP23) (Fig. A) and the accelerator (Gpocket-D. The benzothiazol group shows hydrogen- bonding inter-
actions with the side chains of Arg156 (Fig. 9A). Finally, this mole-
cule was used as a lead molecule for further virtual screening
against the MOE database (Fig. 9B).
In total, 100 hit compounds were sorted out by applying a max-
imum fit value of 85 using 2D finger print analysis. In these set of
100 molecules, the scaffold molecule showed a very good similar-
ity with six representative compounds that was chosen previously
for fluorescence quenching studies against SHaPrPC13 (Fig. S10).
These six molecules were further used for densitometric analysis
with a dose-dependent inhibition of SHaPrPSc formation of ScN2a
cells.2.8. Comparison of ScN2a results with docking studies of six new
inhibitors
The densitometric analysis of previously identified six antiprion
compounds were carried out in a multi well format and PrPSc levels
were measured by immunoblot of proteinase K-digested samples
(Fig. 10).
Cells treated with DMSO (carrier) and quinacrine (a known anti-
prion drug) were used as negative and positive controls, respec-
tively.18 These measurements were used as reference to calculate
the normalized percentage change in PrPSc levels following treat-
ment of previously identified six compounds. Prion infected ScN2a
cells were treated with these six compounds for 5 days at a con-
centration of 10, 20, 50 and 100 mM. Changes in PK-resistant PrPSc
levels were analyzed by Western blots. We were able to confirm
the antiprion activity of these six compounds in reducingPrPSc
levels in ScN2a cells without being cytotoxic. Previous results of
evaluation of the binding affinity between PrPC and these six com-
pounds using fluorescence quenching also confirmed that theseA). The scaffold generated from a set of 10 identified inhibitors (Fig. B).
FP22) (Fig. B) for prion protein inhibition and acceleration from SHaPrPC-SHaPrPSc.
Fig. 10. Six representative compounds fromMOE database that inhibit the PKres PrP
in ScN2a cells.
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may act by stabilizing PrPC, thereby reducing the pool of substrate
for conversion to PrPSc. The compound 3 (6T-0265) interacts with
Arg156 and presents the poorest IC50 of the group showing greater
than 100 mM. This is attributed to possible destabilization of the
salt bridge that is formed with Glu196. The compound 2 (5T-
0214) contains a six-member ring that positions the nitrogen far
enough away to avoid a water mediated hydrogen bond. Although,
the compound does not penetrate deeper into the hydrophobic
pocket, but still shows a better IC50 compared with compound 3
of 35 mM. The other 2-amino pyrimidine compound1 (1G-037)
orients opposite to compound 2 (5T-0214) and buries deeper into
the pocket with a similar IC50 value of 35 mM. The fused ring
structure of compound 6 (6,623,338) works similar to GFP23, in
that it appears to cover the pocket occupied by the o,m-methyl
ether phenyl group with an IC50 of 20 mM. While compound4
(6,413,213) buries much of the pockets surface area, with less
hydrophobic interactions resulting in a weak Kd of 185 mM. FurtherFig. 11. Immunoblot for the compounds 5& 6 that inhibit PrPSc in ScN2a cells
infected with RML strain.disruption of R156’s salt bridge is attributed to its poor IC50 value of
75 mM. Lastly, the compound5 with smaller surface area
(6,872,366) penetrates deep into the hydrophobic pocket and
shows contacts with Arg156’s side chain without disrupting the salt
bridge with Glu196. Thus, it displays a respectable IC50 of 35 mM
due to its binding pocket stabilization effects. Fluorescence
quenching studies showed that compounds 3 and 6 binds with
more stronger affinities with SHaPrPC, with an estimated binding
constant (Kd) of 15.5 and 46.4 mM compared to other 3 compounds
studied.13 This shows that compound3 although binds with higher
affinity shows less inhibition constant compared to other com-
pounds used for the study. Also, the study proves that compound6
is found to be very good inhibitor both in terms of binding and
inhibition of scrapie form PrPSc in ScN2a cells. Furthermore, Immu-
noblots of PrPSc in ScN2a cells infected with RML strain showed
reduction of prion infection signal in the second passage with com-
pound5 and to some extent with compound6, but the signal
returned in passage 3 (Fig. 11).
These results suggest that compounds 5 and 6 acts as promising
leads in developing new antiprion compounds for prion disease
therapy that potentially resists oligomerization.
2.9. Cytotoxicity assay in ScN2a cells infected with a rodent-adapted
RML scrapie strain
Preliminary studies on cytotoxic effect of ScN2a cells as deter-
mined by MTS calorimetric solution showed no significant cell
death in either #6 or #5 at 10, 30 and 100 mM for 21.5 h. Both com-
pounds 6 and 5 didn’t show significant toxicity at 10 and 30 mM.
Moreover, Compound 5 showed no significant difference in cell
viability even at 100 mM concentration.
2.10. Six representative antiprion compounds and EBs stabilizes the
b2-a2 loop through allosteric interactions
The residues of pocket-A within the b2-a2 loop are within
10 Å from the binding pocket-D where EBs and ACCs bind. Exper-
imental evidence implicates this loop region in initiating PrPSc for-
mation and possibly influencing inter species scrapie
transmission.19,20 Our previous fluorescence quenching studies
also proves noscapine binding to pocket-A at the rigid loop and dis-
turb the salt bridge between Arg164/Asp178 initiating prion conver-
sion from SHaPrPC-SHaPrPSc. It was observed that the compounds
EB (GFP23) (Fig. 12A), Bionet1G-037 (Fig. 12B), Bionet5T-0214
(Fig. 12C), Bionet6T-0265 (Fig. 12D), Chembridge6413213
(Fig. 12E), Chembridge6872366 (Fig. 12F), and Chem-
bridge6623338 (Fig. 12G) binding to pocket-D influences the
inward movement of the side chain, Tyr128 of b1 to orient
59.6 ± 10 at Chi-2.
This inward shift of Tyr128 makes the aromatic side chain to
move 3.78Å closer toward Ile182 in a2 to form HAPi interaction
thereby increasing the hydrophobic contact surface. This orienta-
tion of the side chain appears to be an essential feature that could
provide a stabilizing effect on the b1-b2 sheet as well as on the b2-
a2 loop region. The cation-pi interaction is also observed between
the side chains of Gln186, Leu130 and Tyr162 that are separated by
4 Å apart (Fig. 4A). Additionally, in the bound state of the inhibi-
tors, the hydrogen bonding interaction between Tyr128 and the
backbone atom of Leu125 allows nitrogen atom of Arg164 to make
a hydrogen bonding interaction with back bone of Gly127 (Fig. 4A).
Additionally, hydrogen bonds are formed between Tyr163-Cys179
and Tyr162-Thr183 in the inhibitor bound conformations of Bio-
net1G-037, Chembridge-6413213, and Chembridge-6623338. This
shows that the bound state of the b2-a2 loop appears to be more
stable and is most likely preventing an easy transitioning of the
Tyr169 side chain conformation. In the unbound SHaPrPC structure,
Fig. 12. Electrostatic interactions of Pocket-A of SHaPrPC in the bound form of the inhibitors, GFP23 (Fig. A), Bionet1G-037 (Fig. B), Bionet5T-0214 (Fig. C), Bionet6T-0265
(Fig. D), Chembridge 6413213 (Fig. E), Chembridge 6872366 (Fig. F), Chembridge 6623338 (Fig. G).
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Fig. 13. Electrostatic interactions of Pocket-A of native form of SHaPrPC.
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(Fig. 13).
However, Phe175 of a2 shows HAPi interacts with Tyr128 of a3.
This shows that the bound and free states exhibit completely dif-
ferent b2-a2 loop conformations. Furthermore, in the absence of
the ligand, Tyr128 and Ile182 are separated by 5.11Å, disrupting
the potentially stabilizing cation-pi interaction between these side
chains (Fig. 4B). In addition, Tyr169 in the b2-a2 loop shows HAPi
interaction with Val166, while Tyr162 shows hydrogen bonding with
Cys179. The relative positions of the polar residues Arg164, Asp167,
and Gln168 in the b2-a2 loop also change depending on the loop
backbone conformation.
2.11. Accelerators (ACCs) destabilizes the b2-a2 loop
Although binding of an ACC (GFP22) to pocket-D influences the
inward movement of Tyr128 of b1 to form HAPi interaction withFig. 14. Electrostatic interactions of Pocket-A of SHaPrPC in the bound form of the
accelerator (GFP22).Ile182, no cation-pi interactions were observed between the side
chains of Gln186 and Tyr162 residues (Fig. 14). In addition, no HAPi
interaction was seen between Tyr169 of b2-a2 loop with Val166
even though Tyr163 shows hydrogen bonding with Cys179. This ori-
entation of Tyr169 and lack of HAPi interactions between Gln186
and Tyr162 residues may destabilize b1-b2 sheet as well the b2-
a2 loop region.
Overall, the docking studies clearly showed the difference in
binding mode of EBs and six new antiprion compounds with that
of ACCs, although all the three sets of molecules recognize the
same binding pocket-D of SHaPrPC. Structural superposition of
the prion protein SHaPrPC in the free (1B10.pdb) and ligand bound
states of all the EBs, six new antiprion compounds and ACCs have
an overall root-mean-square deviation (rmsd) of 0.3 Å for the Ca
atoms (residues 125–225), indicating that there are no significant
structural changes in the folded prion domain upon compound
binding. However, the side chains of the residues involved in the
interaction with EBs, six new antiprion compounds and ACCs
showed conformational changes that accommodate the hydropho-
bic ligand inside the binding pocket-D. In the bound structure of
the EB (GFP23), the side chain of Phe198 shifts by 1080 at the Cb
position, accommodating a hydrophobic contact with the benza-
mide group of the inhibitor ring. This contact may allow the side
chain to hold the salt bridge Arg156/Glu196/Glu200 within the bind-
ing pocket intact. In the bound conformation of the ACC (GFP22),
the Ca atom of residue Phe198 showed a shift of 4–5 Å that results
in a movement of Arg156 away from Glu196, rendering the binding
pocket more accessible. This result may break the salt bridge
between the residues Arg156/Glu196/Glu200 and allows the protein
to misfolded. We speculate that the SHaPrPC structure of bound
ACCs may represent an inter-mediate stage encountered while
making its passage through the binding pocket. The residues
Met134 in loop1 between b1 and a1, Tyr149 in a1, Met154, Arg156
and Tyr157 in loop 2 between a1 and a2, Ile184 in a2, Gly195,
Asn197 and Phe198 in loop3 between a2 and a3, and Ile205,
Met206, Val209 and Val210 residues in a3 acts as common pharma-
cophores of these EBs and six new antiprion compounds prevent-
ing the SHaPrPC conversion to pathogenic form SHaPrPSc.13 Most
of the residues displaying significant side chain orientation on
binding to these EBs and six new antiprion compounds were found
to cluster into two separate regions of the SHaPrPC. The first region
is the a2-a3 loop and the neighboring residues in helices a2 and
a3. The second region is a1, specifically those residues in contact
with a3. This show that these EBs and new antiprion compounds
show specific interactions commonly at pocket-D of SHaPrPC and
may maintain the salt bridge between Arg156/Glu196/Asp202 intact
for effective antiprion activity. Specifically, these compounds
mainly to interact with Phe198 through hydrophobic contact and
prevent its exposure between the oligomers to generate larger
aggregates.21 The contour maps of CoMFA generated from the 3D
QSAR models built using pharmacophore based alignment high-
light the interaction sites responsible for differences in the biolog-
ical activity. Green indicates the contour regions where the bulky
substituent would increase the inhibitory activity, while the yellow
outline indicates the regions where steric bulk would be unfavor-
able to the inhibitory activity of SHaPrPC. CoMFA contour maps
of the steric and electrostatic properties of the EB (GFP23) gives
the highest affinity with the series (0.11 mM) as shown in Fig. 8A.
The large green contour found around the benzamide group of the
EB (GFP23) indicates that a bulky group of this position provides
support for the high antiprion activity. However, the green counter
is far from 1-(3,3-dimethylcyclohexylidene)piperidinium ring of
the ACC (GFP22) towards solvent exposed. This is perhaps why
the EB (GFP23) with benzamide group that occupy the green coun-
ter in the buried region acts as an inhibitor than the compound
with pyramidine-2 amine that acts as an accelerator. The presence
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unfavorable for the antiprion activity. Moreover, the unfavorable
yellow contour was observed near the di-methylcyclohexylidene
piperidinium ring of the accelerator. This indicates that di-methyl-
cyclohexylidene piperidinium ring would significantly reduce the
aggregation of PrPSc with a mean level of 63.70 ± 5.23. The CoMFA
electrostatic contour mapped marked by red and blue contours,
including red regions show areas where more negatively charged
groups are favorable to inhibitory activity and blue colored regions
represent areas where increased positively charged groups are
favorable to antiprion activity. The red contour map near an oxy-
methyl group indicates that electronegative group is favored at
themeta position of the phenyl ring. The phenyl and 1H indole por-
tion of the EB (GFP23) 1-(3,3-dimethylcyclohexylidene)piperi-
dinium ring and pyramidine-2 amine of the ACC (GFP22) are
occupied by large blue contours due to the presence of the elec-
tron-withdrawing nitrogen atoms. The large blue contour shows
that an electron-deficient nature is important for high binding
affinity. The electronegative carbonyl oxygen atom of the oxy-
methyl group forms a favorable contact with the positively charged
nitrogen atom of Asn197 surrounded by a blue contour. The electro-
static interactions with these backbone atoms are essential for dif-
ferentiation in potency of the EB (GFP23) and ACC (GFP22). The red
contours with the high electron density of the EB (GFP23) are in
close proximity to the electronegative group of Met206-SCH3 justi-
fying the presence of red and yellow contours. However, the red
contours with the high electron density of the ACC are solvent
exposed without showing any contact indicating the role in prion
misfolding. Our NMR chemical shift data also indicate that EB
(GFP23) binding perturbs the interface between helices a2-a3,
supporting the idea that EB (GFP23) binding may allosterically
enhanced the packing between the helices. This flexible prion
region, the C-terminal part of helix a2 and the a2-a3 loop, is the
recognition site for antiprion compound GN8, a small molecule
that prolongs the survival of TSE-infected mice.8 The results also
showed that residues such as Phe198 in the a2-a3 loop, and
Val203, Met206, and Val210 in a3 also show chemical shifts changes
for the backbone amides along with Thr188 within a2. As a result,
the relative orientation between a1 and a3 is 70.22 This orien-
tation further stabilizes the salt bridge between Arg156/Glu196
using a2-a3 loop only in SHaPrPC (1uw3). These strong interac-
tions are not found in either huPrP, in which this region is involved
in the hinge of the swapped dimer, or antibody-bound SHaPrPC,
being this region the antibody epitope. These specific interactions
may also be advantageous to reducing side effects. Previous 1H–
15N HSQC spectra of PrPC with or without GJP49 shows the specific
binding of GJP49 to the C-terminal region of a2 and at part of the
a2-a3 loop of PrPC with a dissociation constant (Kd) of 50.8 mM.15
Further, six active antiprion compounds that were previously iden-
tified were tested by a high-throughput, ELISA-based assay utiliz-
ing ScN2a cells. Reductions in the expression level of SHaPrPC by
two new antiprion compounds at 20 (compound 6) and 32 mM
(compound 5) concentration represent a promising mechanism
of action for prion pathogenic inhibition from PrPC-PrPSc. The com-
pounds 6 and 5 have not shown any sign of toxicity in a standard
MTS assay at 30 mM concentration. However, compound6 with
high antiprion activity with IC50 of 20 mM compared to compound5
raises the possibility that compound6 might serve as a lead com-
pound for prion therapy. These results and previous fluorescence
quenching studies suggest that all of these six new antiprion com-
pounds directly interacted with recombinant SHaPrPC in GN8 bind-
ing site. Although the mechanisms of action of these compounds
are unclear in vitro, fluorescence quenching analysis suggests that
they are likely to interact directly with SHaPrPC at pocket-D and
may stabilize the slat bridge between Arg156/Glu196/Glu200. Thus,these six new antiprion compounds can be referred to as ‘‘medical
chaperones’’ that stabilized the native conformation of the target
protein SHaPrPC and inhibit its transition to the abnormal confor-
mation, SHaPrPSc. Thus, based on the present and previous studies,
it can be stated that compound6 stabilizes SHaPrPC specifically
more than any other compound used in the study and could be
used as a therapeutic candidate for prion diseases.3. Conclusions
In this study, we have successfully combined the docking,
HQSAR, CoMFA, NMR and cell based assays to observe the binding
effect of EB (GFP23), ACC (GFP22) on prion stabilization and mis-
folding. The good correlation obtained between the molecular
docking and experimental studies show that the EBs, ACCs bind
to pocket-D of SHaPrPC. In addition, the docking results also show
that the EBs maintain the salt bridge between Arg156-Glu196 while
ACCs disturb the salt bridge. In addition, virtual screening of the
compounds database using the molecular scaffold identified six
compounds in the ranking list of 100 that were previously identi-
fied as antiprion compounds. The compounds 6 & 1, 2 & 5 with
an estimated IC50 value of 20 mM and 35 mM shows significant
effect in reducing accumulation of SHaPrPSc in ScN2a cells in the
micromolar range. These were non-toxic to cultured cells with
good bioavailability consistent with central nervous system. Fluo-
rescence quenching and computational studies conducted previ-
ously on these six compounds showed that compound6 bind to
pocket-D of SHaPrPC with a Kd value of 44 mM and in addition
may effectively maintains the salt bridge between Arg156/Glu196/
Glu200. In combination, our results also indicate that newly
screened compound6 is more potent than other compounds in sta-
bilize SHaPrPC in preventing its conversion into SHaPrPSc. Thus, this
study will be useful for the designing more novel compounds using
compound6 for prion protein inhibition from PrPC to PrPSc. These
results also indicate that our computational studies show very
good correlation with experimental studies.4. Methodology
4.1. Molecular docking
For In silico docking in MOE (Chemical computing group, Mon-
treal, Canada), the ligand placement method ‘‘Alpha PMI” was
employed using London dG scoring function using implicit gener-
alized born solvation model.23 The simulated annealing based on
the Monte Carlo method was used to find the global minimum of
the ligand. It explores various states of a configuration space by
generating small random changes in the current state and then
accepts or rejects each new state according to the Metropolis crite-
rion.24 The ligand was optimized by energy minimization with the
Tripos Assisted Force Field (TAFF) until the energy gradient is
below 0.001 kcal/Mol.25 By default, thirty conformations docked
as a cut-off were retained. Finally, affinity scoring function, DG
(Utotal in kcal/mol), was employed to rank a candidate poses as
the sum of the electrostatic and Van der Waals energies. This
method may generate bound conformations that resemble resolu-
tions close to crystallography.26 The dielectric function based on
the reaction model with a cut-off between 8 and 10 Å was used
for our docking studies with the pocket radius of 6. The pharma-
cophoric model that was generated using recap synthesis and
binds with higher affinity in pocket-D was used as a scaffold for
virtual screening. The compounds with maximum fit value of 85
were chosen for ScN2a cell based assay to determine the IC50 val-
ues against the conversion of PrPC to PrPSc.
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NMR spectra were acquired at 25 C on a 500 MHz Varian Unity
INOVA spectrometer fitted with a 5 mm HCN z-gradient pulsed-
field gradient cryogenic probe except for the STD-TOCSY, which
was collected at 25 C on an 800 MHz Varian Unity INOVA spec-
trometer fitted with a 5 mm HCN xyz-gradient pulsed-field gradi-
ent cryogenic probe. All experiments were collected using Varian
BioPack pulse sequences (VNMRJ v2.1B). Spectra were processed
using nmrpipe and analyzed with nmrpipe and nmrviewj unless
stated otherwise.27 Both inhibitor (GFP23) and accelerator
(GFP22) used in the study was purchased from Sigma-Aldrich (St.
Louis, MI, USA), and used without further purification. To collect
the first NOESY NMR spectrum, each compound was dissolved in
20 mm potassium phosphate buffer at pH 6.5 giving a final concen-
tration of 100 lm. Ten percent (v/v) D2O was added to each sample
to maintain a spectral lock, 1 mm of 2,2-dimethyl-2-silapentane-5-
sulfonate was added for chemical shift referencing.28 For each 1D
NOESY spectrum, 48,000 points were averaged from 256 transients
over a sweep width of 6000 Hz. A recycle delay of 0.01 s and an
acquisition time of 4 s were used. The mixing time for the screen-
ing experiments was 100 ms. Immediately following collection of
the reference compound spectra, the NMR sample was used to
reconstitute prealiquoted, lyophilized SHaPrPC (90–232) and a sec-
ond spectrum was collected with the same parameters. The molar
ratio of protein to each compound was 1:1. Matching spectra were
superposed and analyzed with the Chenomx NMR suite v6.0 to
assess chemical shift and linewidth perturbations of the metabolite
signals. To collect the 2D 15N-HSQC titration spectra, a reference
15N-HSQC spectrum of the SHaPrPC (90–232), alone, was first col-
lected (300 lm, 350 lL, 20 mm KH2PO4, pH 7 and 6.2). These 15N-
HSQC reference spectra were collected with 2048 complex points
in the 1H dimension and 256 complex points in the 15N dimension
using a recycle delay of 1.5 s (nt = 120, sw = 6000 Hz,
sw1 = 1800 Hz). Each compound was successively added to con-
centrations of 1, 2, 5 and 10 mm and the 15N-HSQC spectra recol-
lected using identical acquisition parameters. The amide chemical
shift data for the EB (GFP23) and ACC (GFP22) complex has been
deposited into the {[1-(2-methylpropyl)-1H-benzimidazol-2-yl]
sulfanyl}BioMagResBank (BMR17834).
4.3. HQSAR and CoMFA analysis of EB (GFP23) and ACC (GFP22)
The series of antiprion compounds used for the HQSAR and
CoMFA analysis include EBs and ACC derivatives were obtained
from a report published by Hosokawa-muto et al.8 The report con-
sists of 27 compounds with mean level of PrPSc using two to four
independent experiments (Table 5).
The compound structures were built in SybylX2.0 molecular
modeling package and Gasteiger–Marshili charges were assigned
to the atoms of the compounds. All the compounds were energy
minimized until the gradient convergence of 0.001 kcal1 A1
was reached using Tripos force field (http://www.tripos.com/).
The compounds in the dataset were divided into training and test
set. From these 25 compounds, only 21 compounds were selected
as training set and four compounds (1, 9, 16 and 24) were taken as
a test set. The mean values of the training set were converted into
their logarithmic form (log50) and subsequently used as depen-
dent variables in the HQSAR analysis. The compounds in the train-
ing set were used to derive the model whereas; the compounds in
the test set were used to evaluate the predictability of the model.
4.4. 2D fingerprint based similarity search
The 2D similarity searches were performed with the software
MOE [Molecular Operating Environment Montreal, Quebec,Canada: Chemical Computing Group, Inc.; 2007] using two-point
(typed graph distances (TGD) and three-point (typed graph trian-
gles (TGT) pharmacophore-based fingerprints, all calculated from
a 2D molecular graph. Each atom was given a type among donor,
acceptor, polar, anion, cation, or hydrophobe for the calculation
of TGD and TGT. Subsequently, pairs (two-point fingerprint) or tri-
plets (three-point fingerprints) of types were formed by graph dis-
tances and coded as sparse features in a fingerprint. The Tanimoto
coefficient was used as the similarity metric.29 The Tanimoto coef-
ficient between two molecules described by a 2D fingerprint is cal-
culated using the following expression:
Tab ¼ C=aþ b c
where ‘‘c” is the number of bits common to the two molecules, and
‘‘a” and ‘‘b” denote the number of bits set in each of the two
fingerprints.4.5. ScN2a cell line assay-1
The chemical library of six compounds that were used for
screening in cell-based assays was commercially obtained from
BioNet and Chembridge databases.13 Compounds were solubilized
at 10 mm in dimethyl sulfoxide (DMSO)2 and stored in a 96-well
format. Furthermore, a mouse neuroblastoma (N2a) cell line was
infected with the Rocky Mountain Laboratory (RML) strain of scra-
pie prions to produce ScN2a cells.30 Screening the chemical library
for antiprion activity was performed in a high-throughput ELISA.
Briefly, 4  104 ScN2a cells were treated with these six compounds
of interest for 21.5 h at 10, 20, 50 and 100 mM concentrations.
ScN2a cells treated with quinacrine (1 lm) were used as positive
controls while cells treated with DMSO alone was used as Negative
controls.18,31 Cells were lysed with lysis buffer (0.5% Nonidet P-40,
0.5% deoxycholate, 10 mm Tris-HCl, pH 8, 100 mm NaCl) and pro-
tein concentration was normalized to 1 mg/ml using the BCA assay.
Samples were incubated with 20 lg/ml of proteinase K for 1 h at
37 C. Digestions were stopped with 2 mm phenylmethylsulfonyl
fluoride (PMSF), and samples were centrifuged at 100,000g for
1 h at 4 C. Supernatants were discarded, and pellets were re-sus-
pended in reducing SDS sample buffer for SDS-PAGE. After treat-
ment and cell lysis, normalized crude extracts were analyzed by
Western immunoblotting using conjugated 6D11-biotin antibody
to detect PrP. For dose–response analysis, ScN2a cells were treated
for 21.5 h at 10, 20, 50 and 100 mM and quantified by Western
immunoblotting as described above.4.6. ScN2a cell line assay-2
Mouse neuroblastoma cell lines (N2a) infected with a rodent-
adapted RML scrapie strain were treated with prion conversion
inhibitors and were tested for ongoing infection by immunoblot
assay of protease resistant prion protein (PrPSc) in cell lysates. Cell
cultures were treated with individual therapeutic compounds
including compounds 5 & 6 with fresh drug present in the media
with each passage and cell collection every 2–3 days. Samples
were taken though multiple passages to allow clearance of infec-
tion and monitoring for any adaptation resulting in re-emergence
of a drug-resistant or drug-dependent strain of PrPres.4.7. Cytotoxicity assay in ScN2a cells infected with a rodent-adapted
RML scrapie strain
For preliminary toxicity experiments, cultures were plated onto
96-well plates in triplicates for 21.5 h at different concentrations of
compound6 (3 mM, 10 mM, 30 mM) and compound 5 (10 mM, 30 mM
5888 N.S. Pagadala et al. / Bioorganic & Medicinal Chemistry 25 (2017) 5875–5888and 100 mM). Cytotoxicity was evaluated by the 3-[(4,5-dimethyl-
thiazol-2-yl)-5,3-carboxymethoxyphenyl]-2-(4-sulfophenyl)-2H
tetrazolium, inner salt (MTS) reduction assay (Promega). Cells were
incubated with MTS solution (2 mg/mL) for 2 h at 37 C in a 5% CO2
incubator, then read at 490 nm using a Spectramax M5 spec-
trophotometer. P values lower than 0.05 were considered
significant. Cell viability was calculated as percent of control, with
control being non-treated cells.
A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmc.2017.09.024.
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